Aclarion, Inc. will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California, where CEO Brent Ness will meet with institutional investors and analysts to discuss the company's progress and future catalysts. The commercial-stage healthcare technology company focuses on leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain through its Nociscan platform.
The importance of this development lies in addressing a significant healthcare challenge: chronic low back pain affects millions of people worldwide, often leading to reduced quality of life, lost productivity, and substantial healthcare costs. Current diagnostic methods can be imprecise, making targeted treatment difficult. Nociscan represents a technological advancement that could provide more accurate identification of painful discs, potentially leading to better treatment outcomes and reduced healthcare expenditures.
During the conference, Ness will highlight the company's strong financial position, noting that Aclarion maintains a strong balance sheet with no debt. This financial stability supports the company's focused strategy to expand adoption of Nociscan in both the United Kingdom and United States markets. The company believes this positioning enables execution on what it views as a significant market opportunity in the chronic pain management sector.
Nociscan operates as a Software-as-a-Service platform that receives magnetic resonance spectroscopy data from MRI machines via cloud connection. Proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain, which are then analyzed through proprietary algorithms to indicate whether a disc may be a pain source. When used alongside other diagnostic tools, this technology provides physicians with critical insights to optimize treatment strategies for individual patients.
The potential impact of this technology extends beyond individual patient care to broader healthcare systems. More precise diagnosis could reduce unnecessary procedures, shorten treatment timelines, and decrease overall healthcare costs associated with chronic low back pain management. For the medical technology industry, Aclarion's approach demonstrates how combining advanced imaging, biomarker analysis, and artificial intelligence can address complex diagnostic challenges.
For more information about Aclarion and its technology, visit https://www.aclarion.com. Additional company news and updates are available through the company's newsroom at https://tinyurl.com/aconnewsroom. The company's participation in the ROTH Conference represents an opportunity to communicate its progress to the investment community as it advances its clinical and commercial objectives in the healthcare technology sector.
